Model N to Present at the JMP Securities Technology Conference

SAN MATEO, Calif.–(BUSINESS WIRE)–Model N, Inc. (NYSE: MODN), the leading provider of cloud revenue management solutions for life sciences and high tech companies, today announced that Jason Blessing, president and CEO, will present at the JMP Securities Technology Conference in San Francisco, CA.

This presentation is scheduled for Monday, February 24, 2020, at 10:00 a.m. PT or 1:00 p.m. ET. A live webcast of the presentation will be accessible from the investor relations page of the Model N website at https://investor.modeln.com/.

About Model N

Model N is a leading provider of cloud revenue management solutions for life sciences and high tech companies. Our software helps companies drive mission-critical business processes such as pricing, quoting, contracting, regulatory compliance, rebates and incentives. With deep industry expertise, Model N supports the complex business needs of the world’s leading brands in pharmaceutical, medical technology, semiconductor, and high tech manufacturing across more than 120 countries, including Johnson & Johnson, AstraZeneca, Novartis, Microchip Technology and ON Semiconductor. For more information, visit www.modeln.com.

Model N® is the registered trademark of Model N, Inc. Any other company names mentioned are the property of their respective owners and are mentioned for identification purposes only.

Contacts

Investor Relations Contact:
Gwyn Lauber

Model N, Inc.

650-610-4998

investorrelations@modeln.com

Media Contact:
Laura Ruark

Bospar

laura@bospar.com

Staff

Recent Posts

Mixie Technologies, Inc. (PHCG) Announces CES Picks Award Recognition for HoloTwin LLC

Recognition by TechRadar Pro at CES 2026 underscores the strategic rationale behind Mixie’s strategic investment…

1 second ago

HealthEquity Announces Fiscal Year 2027 Outlook Presentation at J.P. Morgan Healthcare Conference

DRAPER, Utah, Jan. 12, 2026 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the…

6 seconds ago

Achieve Life Sciences Confirms Promotion of Dr. Mark Rubinstein to Chief Medical Officer

Experienced medical executive advances to permanent role following successful leadership as Interim CMOSEATTLE and VANCOUVER,…

16 seconds ago

ACCENT DATA PRESENTED AT 2026 ASCO GASTROINTESTINAL CANCER SYMPOSIUM

HIGHLIGHTS Results from the Phase 2a ACCENT trial in pancreatic cancer have been presented at…

25 seconds ago

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones

 -2026 is poised to be a data- and milestone-rich year across the portfolio- -CASGEVY® launch…

45 seconds ago